Clinical trial · Observational
Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer
A Retrospective Clinical Study of Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Carcinoma.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to investigate the efficacy and safety of stereotactic body radiotherapy combined with PD-1 blockers for LAPC and LRPC. The patients, diagnosed with locally advanced pancreatic cancer (LAPC) or locally recurrent pancreatic cancer (LRPC). LRPC or LAPC, undergoing SABT and PD-1 blockers in our hospital from December 2020 to April 2023 were reviewed consecutively. All patients provided written informed consent before treatment. The study was conducted in accordance with the Declaration of Helsinki, and it was approved by the Institutional Ethics Committee of Peking University Third Hospital.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
| PD-1 Inhibitors | — | UNRESOLVED | — |
| Stereotactic Body Radiotherapy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PD-1 blocking antibody | Drug | — | UNRESOLVED |
| Stereotactic body radiotherapy (SBRT) | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- SBRT+PD-1 blockers
- description
- pembrolizumab (200 mg every 3 weeks), carelizumab (200 mg every 3 weeks), tislelizumab (200 mg every 3 weeks), sintilimab (200 mg every 3 weeks), zimberelimab (240 mg every 3 weeks) until the tumor progressed or the side effects became intolerable.
- interventionNames
- Radiation: Stereotactic body radiotherapy (SBRT)
- Drug: PD-1 blocking antibody
Primary outcomes (1)
- measure
- progression-free survival (PFS)
- timeFrame
- 12 months
- description
- PFS was defined as the time from SBRT to disease progression
Secondary outcomes (4)
- measure
- local progression-free survival (LPFS)
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. LRPC confirmed by pathologic or imaging diagnosis and LAPC confirmed by pathology; 2. disease size ≥1 cm; 3. KPS≥70; 4. adequate hematological reserves, hepatic function, renal function and heart function; 5. expected survival \> 3 months. Exclusion Criteria: 1. unconfirmed mass; 2. The upper abdomen was previously treated with radiotherapy; 3. the patients previously underwent immunotherapy of PD-1 or PD-L1 monoclonal antibody; 4. a history of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency or other immune-related conditions requiring long-term oral hormone therapy; 5. patients with active infectious disease, trauma and severe wounds; 6. patients with any mental disorder; 7. patients with other somatic comorbidities of clinical concern; 8. pregnancy and lactation.
References
Publications (0)
Data not yet available